Toll样受体激动剂促进三级淋巴结构形成并改善抗胶质瘤免疫
本研究通过颅内给予Toll样受体激动剂OK-432与胶质瘤抗原诱导胶质瘤微环境中三级淋巴结构形成,利用染色分析、抗体中和、单细胞RNA测序及BCR/TCR测序探讨机制,并开展初步转化临床研究;结果显示三级淋巴结构形成与淋巴细胞浸润增加及荷瘤小鼠预后改善相关,CD4+和CD8+ T细胞而非CD19+ B细胞参与抗胶质瘤免疫,颅内αTLR-mix治疗耐受性良好。
要点
- 颅内给予TLR激动剂OK-432与胶质瘤抗原可诱导胶质瘤微环境中三级淋巴结构形成。
- 三级淋巴结构形成与淋巴细胞浸润增加及荷瘤小鼠预后改善相关。
- CD4+和CD8+ T细胞而非CD19+ B细胞参与三级淋巴结构形成后的抗胶质瘤免疫。
核心结论
- 胶质瘤微环境中诱导三级淋巴结构形成可增强抗胶质瘤免疫、改善免疫微环境并控制胶质瘤生长,提示未来治疗胶质瘤的潜在途径。
研究设计与样本
- 通过颅内给予Toll样受体激动剂(OK-432,TLR2/4/9激动剂)和胶质瘤抗原(颅内αTLR-mix)诱导胶质瘤微环境中三级淋巴结构形成。
- 采用染色分析、抗体中和、单细胞RNA测序及BCR/TCR测序研究三级淋巴结构形成的机制及其在抗胶质瘤免疫中的作用。
- 开展了一项初步转化临床研究。
主要发现
- 三级淋巴结构形成与胶质瘤微环境中淋巴细胞浸润增加相关,并导致荷瘤小鼠预后改善。
- 某些巨噬细胞/小胶质细胞和Th17细胞分别显示LTo和LTi细胞标志物,通过LTα/β-LTβR相互作用促进三级淋巴结构诱导。
- 三级淋巴结构形成后,CD4+和CD8+ T细胞而非CD19+ B细胞参与抗胶质瘤免疫。
- 脑与淋巴结B/T细胞比较分析显示脑B/T细胞呈现从初始到成熟的转换,部分B细胞显示类别转换重组相关基因富集,并观察到V基因使用和克隆型偏倚。
- 在相关临床研究中,颅内αTLR-mix治疗表现出耐受性,趋化因子/细胞因子检测提供初步证据支持胶质瘤微环境中三级淋巴结构形成。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioma, characterized by limited lymphocytic infiltration, constitutes an "immune-desert" tumor displaying insensitivity to various immunotherapies. This study aims to explore therapeutic strategies for inducing tertiary lymphoid structure (TLS) formation within the glioma microenvironment (GME) to transition it from an immune resistant to an activated state. METHODS: TLS formation in GME was successfully induced by intracranial administration of Toll-like receptor (TLR) agonists (OK-432, TLR2/4/9 agonist) and glioma antigens (i.c. αTLR-mix). We employed staining analysis, antibody neutralization, single-cell RNA sequencing (scRNA-Seq), and BCR/TCR sequencing to investigate the underlying mechanisms of TLS formation and its role in anti-glioma immunity. Additionally, a preliminary translational clinical study was conducted. RESULTS: TLS formation correlated with increased lymphocyte infiltration in GME and led to improved prognosis in glioma-bearing mice. In the study of TLS induction mechanisms, certain macrophages/microglia and Th17 displayed markers of "LTo" and "LTi" cells, respectively, interaction through LTα/β-LTβR promoted TLS induction. Post-TLS formation, CD4 + and CD8 + T cells but not CD19 + B cells contributed to anti-glioma immunity. Comparative analysis of B/T cells between brain and lymph node showed that brain B/T cells unveiled the switch from naïve to mature, some B cells highlighted an enrichment of class switch recombination (CSR)-associated genes, V gene usage, and clonotype bias were observed. In related clinical studies, i.c. αTLR-mix treatment exhibited tolerability, and chemokines/cytokines assay provided preliminary evidence supporting TLS formation in GME. CONCLUSIONS: TLS induction in GME enhanced anti-glioma immunity, improved the immune microenvironment, and controlled glioma growth, suggesting potential therapeutic avenues for treating glioma in the future.
引用
- Shen S, Cui Y, Li M, et al. Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity. Neuro Oncol. 2025. PMID: 39188155. doi:10.1093/neuonc/noae167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。